A missense mutation in the NF2 gene results in moderate and mild clinical phenotypes of neurofibromatosis type 2.
Since the identification of the NF2 tumor suppressor gene in 1993, various mutations have been found in NF2-related tumors and in lymphocytes from NF2 patients. Most of the reported mutations result in truncated gene products. Missense mutations affecting the tumor suppressor are rare. These missense mutations would provide valuable information for the understanding of the function of the tumor suppressor, since they should affect critical parts of the protein. In this study we describe a novel point mutation in exon 15 of the NF2 gene, which is found in lymphocyte DNA of two NF2 patients from one family. This mutation is expected to result in a substitution of Pro for Gln at codon 538. Though both of the two patients developed bilateral vestibular schwannomas, the first patient showed onset of the disease at the age of 31 years and presented with various central, peripheral and abdominal tumors, while the second patient showed later onset of clinical symptoms (at age 52 years) and presented with only two additional small spinal tumors.
Kluwe
L
L
Department of Neurosurgery, University Hospital Eppendorf, Hamburg, Germany.
Mautner
V F
VF
D000328:Adult; D001483:Base Sequence; D004247:DNA / Q000097:blood; D004252:DNA Mutational Analysis; D005091:Exons / Q000235:genetics; D005260:Female; D016515:Genes, Neurofibromatosis 2 / Q000235:genetics*; D034381:Hearing Loss; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009442:Neurilemmoma; D016518:Neurofibromatosis 2 / Q000235:genetics*; D010375:Pedigree; D010641:Phenotype; D017354:Point Mutation / Q000235:genetics*; D014012:Tinnitus
D004247:DNA